MEAGAN ADAMSICK, PHARMD*

Articles by MEAGAN ADAMSICK, PHARMD*

Entering the Phase of Phage: A Closer Look at Bacteriophage Therapy

ByMEAGAN ADAMSICK, PHARMD*

December 20th 2020

The Early Bird Gets to Stay Home: Early OPAT Follow-Up Reduces 30-Day Readmissions

ByMEAGAN ADAMSICK, PHARMD*,MONIQUE R. BIDELL, PHARMD, BCPS

February 11th 2020

Readmission rates for patients receiving OPAT are reported to be as high as 20%, mostly due to catheter-related problems, adverse drug reactions, or worsening of the primary infection.

Latest Updated Articles

Entering the Phase of Phage: A Closer Look at Bacteriophage Therapy
December 20th 2020
The Early Bird Gets to Stay Home: Early OPAT Follow-Up Reduces 30-Day Readmissions
February 11th 2020

MEAGAN ADAMSICK, PHARMD*

Articles by MEAGAN ADAMSICK, PHARMD*

Entering the Phase of Phage: A Closer Look at Bacteriophage Therapy

The Early Bird Gets to Stay Home: Early OPAT Follow-Up Reduces 30-Day Readmissions

Latest Updated Articles

Trending on Contagion Live

Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics

Washington State Reports First US Avian Influenza Death of 2026

FDA Tentatively Approves First Generic Lenacapavir PrEP for 120 LMICs

Postapproval Surveillance Confirms Ceftobiprole Activity Against MRSA

FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis